GlassScriptPhysician profile
Henry B Stamps
NPI 1548373947
$11,946.29
in general payments reported to CMS, 2019-2025
55 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,864 · 2020: $1,497 · 2021: $2,081 · 2022: $1,832 · 2023: $1,565 · 2024: $1,785 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,666 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,666.01 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,285.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,382.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $917.17 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $692.24 | 2019-2025 | Vraylar, Creon, Linzess |
| Pfizer INC. | $512.98 | 2019-2025 | |
| Abbott Laboratories | $439.97 | 2021-2025 | Freestyle Libre 3, Eterna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $424.77 | 2019-2025 | Xifaxan, Trulance |
| Amgen INC. | $401.44 | 2019-2025 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $387.10 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $385.90 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.32 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $340.05 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $277.13 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.73 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $224.05 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Stamps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.